Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre‐transplant minimal residual disease reduction
Nirali N. Shah(National Institutes of Health), Alan S. Wayne(University of Southern California), Brent L. Wood(University of Southern California), Terry J. Fry(University of Colorado Anschutz Medical Campus), Deepa Bhojwani(St. Jude Children's Research Hospital), Inna Vainshtein(Exelixis (United States)), Lewis B. Silverman(Columbia University Irving Medical Center), Denison Kuruvilla(AstraZeneca (Australia)), Kirk R. Schultz(University of British Columbia), Alexia Adams(National Marrow Donor Program), Jennifer Schneiderman(Northwestern University), Sonali Chaudhury(Northwestern University), James A. Whitlock(Hospital for Sick Children), Dennis L. Confer(National Marrow Donor Program), Paul L. Martin(Duke University), Michael A. Pulsipher(Primary Children's Hospital)
Cited by 5
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934